SPT Labtech, a global leader in laboratory automation and liquid handling solutions, and Alithea Genomics, a pioneer in large-scale RNA sequencing and transcriptomics, have announced a partnership to deliver automated solutions for single-cell transcriptomics.
This collaboration integrates Alithea Genomics’ ultra-sensitive single-cell RNA-seq technology, MERCURIUS™ FLASH-seq, with SPT Labtech’s Firefly® liquid handling platform to create scalable and reproducible workflows for transcriptomic research. The automated workflow is immediately available to global customers through the application support teams of both companies.
Technological Integration and Workflow Innovation
The partnership combines Alithea Genomics’ MERCURIUS FLASH-seq, a novel single-cell RNA-seq protocol that provides exceptional gene detection sensitivity for ultra-low input samples and single cells, with the precision low-volume dispensing capabilities of SPT Labtech’s Firefly platform.
This integration addresses critical bottlenecks in single-cell research by automating sensitive RNA-seq protocols, enhancing reproducibility, throughput, and accessibility. The Firefly’s modular architecture supports both discovery-scale and large-scale experimental designs, ensuring consistent results across varying throughput requirements.
Industry Challenges and Solution Benefits
Single-cell transcriptomics represents a rapidly advancing field driving progress in cell biology, immunology, and drug discovery. However, many workflows remain constrained by manual library preparation steps that introduce variability and limit throughput.
This collaboration directly addresses these limitations by combining Firefly’s precision liquid handling with Alithea Genomics’ scalable RNA sequencing chemistry. The automated solution enables researchers to achieve new levels of efficiency, reproducibility, and throughput in their single-cell studies.
Executive Commentary and Technical Advantages
Morten Frost, Chief Commercial Officer at SPT Labtech, commented: “This collaboration represents a significant step toward broader automation of complex RNA workflows, supporting the increasing integration of transcriptomics into translational and clinical research.
By implementing this workflow on Firefly, laboratories can elevate their efficiency, reproducibility, and throughput to new levels.” The partnership leverages Alithea Genomics’ recognition for transforming RNA sequencing through scalable and cost-effective solutions.
Application Support and Immediate Availability
The automated workflow is now readily accessible worldwide through the combined application support infrastructure of both companies. Researchers can benefit from comprehensive technical support and implementation guidance, ensuring smooth adoption and optimal performance of the integrated system.
This immediate availability enables research institutions to accelerate their single-cell transcriptomics programs without the traditional barriers associated with method development and validation.
Future Implications and Market Impact
As demand grows for higher-throughput, more cost-effective single-cell sequencing solutions, the ability to automate sensitive RNA-seq protocols becomes increasingly crucial for both academic and research environments.
This partnership not only addresses current challenges in single-cell research but also paves the way for more extensive integration of transcriptomic analyses in clinical and translational settings. The collaboration represents a significant advancement in making sophisticated single-cell technologies more accessible and reproducible across the research community.
Related topics:
